AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.520
+0.004 (0.85%)
At close: Apr 28, 2026, 4:00 PM EDT
0.522
+0.002 (0.44%)
After-hours: Apr 28, 2026, 4:17 PM EDT
AIM ImmunoTech Employees
As of December 31, 2025, AIM ImmunoTech had 21 total employees, including 19 full-time and 2 part-time employees. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
$4,190
Profits / Employee
-$664,667
Market Cap
4.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 47 |
| VivoSim Labs | 14 |
| Soligenix | 14 |
| Azitra | 13 |
| Revelation Biosciences | 9 |
| Alzamend Neuro | 6 |
| Galmed Pharmaceuticals | 6 |
| 60 Degrees Pharmaceuticals | 3 |
AIM News
- 12 days ago - AIM ImmunoTech Transcript: Virtual Investor Closing Bell - Transcripts
- 14 days ago - AIM ImmunoTech Provides Routine Update on Annual Filings - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - GlobeNewsWire
- 7 weeks ago - AIM ImmunoTech Announces Closing of its Rights Offering - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Transcript: Virtual Investor Closing Bell - Transcripts